Aims of this study: To evaluate the ef®cacy of chronic and`on demand' administration of paroxetine hydrochloride in the drug treatment of premature ejaculation (PE).
Introduction
Premature ejaculation (PE) is the most common male sexual disorder, affecting perhaps as many as 75% of men at some stage in their sexual lives. Premature ejaculation is invariably psychogenic due to performance anxiety, fear or psychological trauma and has historically been treated predominantly by psychosexual counselling. However, many men decline or fail to complete a trial of psychosexual counselling as treatment for PE for a variety of reasons. Men may decline treatment with psychosexual counselling as a result of their non-acceptance of counselling as a valid treatment due to incorrectly assumed social stigma associated with attending a psychiatrist or psychologist. Some men may be unable or not prepared to devote the time required to attend several counselling sessions. Other men may demand a quicker response than psychosexual counselling is reported to offer. Optimal results with psychosexual counselling are highly dependant on the cooperation of the sexual partner of the man in attending and actively participating in the counselling sessions. Many men do not have a current sexual partner or may have a non-compliant sexual partner. Clearly, a signi®cant treatment`hiatus' exists in the management of PE which may be ®lled by alternate noncounselling treatment methods.
Delayed ejaculation is a common adverse effect of many psychotropic and antidepressant drugs which act centrally andaor locally to retard the psychoneurological control of ejaculation and subsequent orgasm. Animal studies have shown that the central neurotransmitter serotonin has an inhibitory effect on sexual function, while dopamine is generally stimulatory. 1 Sexual effects can occur through any shift in this serotonin-dopamine balance by an increase or decrease in either or both neurotransmitter. The serotonin re-uptake inhibitors (SSRI) should reduce sexual arousal and have a bene®cial effect on premature ejaculation.
There have been multiple reports in the literature regarding the sexual adverse effects of antidepressant drugs and their potential use as treatment for PE. Deveaugh-Geiss et al 2 in a multi-centre study reported failure of ejaculation in 42% of 520 men treated for depression with 200 mg chlomipraminead. Monteiro et al 3 reported a double blind study which showed even greater sexual dysfunction in depressed men treated with chlomipramine, among 17 men, ejaculation was delayed in three and absent in 14. Girgis et al 4 and Althof et al 5 reported success in the actual treatment of PE with chlomipramine.
Patterson 6 noted retarded or absent ejaculation in 45 out of 60 male men treated with 20 mgad uoxetine for depression. Kara et al 7 in a double blind placebo controlled study of¯uoxetine demonstrated a seven fold increase in the ejaculatory interval which was noted as early as one week after initiation of treatment. Crenshaw 8 reported a dose related improvement in ejaculatory control in 46 men with¯uoxetine treatment of PE. He noted that some men maintained improved ejaculatory control after withdrawal of¯uoxetine after 3 ± 6 months of treatment. Waldinger et al, 9,10 , Giammusso et al 11 and Ludovico et al 12 reported signi®cant improvement in ejaculatory control with paroxetine. McMahon, 13 
Materials and methods
Ninety-four normally potent men suffering from PE were enrolled in a prospective study to assess the ef®cacy and tolerance of paroxetine hydrochloride (Aropax 1 ) in the management of PE. All of the study group were heterosexual, had no other sexual disorders and were either married or in a stable relationship. Baseline pre-treatment ELT was determined as the mean of measurements at a minimum of two intercourses (mean 2.2, range 2 ± 3) prior to commencement of the study using a stop watch operated by the patient. All patients enrolled in the study had an ELT less than 1 min and were regarded as having severe PE.
Premature ejaculation was regarded as ejaculation that occurred within 60 s of intromission. Men with erectile dysfunction, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse and the use of medication, including psychotropic medication were excluded from the trial. Men were asked not to use condoms, topical penile anaesthetic creams or sprays. None of the men received any formal psychosexual counselling.
Men in this study were enrolled into two groups, group A and group B. Men enroled in group A initially received paroxetine 20 mg daily for four weeks (Phase 1). Men in Group A who responded with improved ejaculatory control were then treated with a single dose of paroxetine (20 mg) administered`on demand' 3 ± 4 h prior to planned intercourse (Phase 2) for a further four weeks. Men enrolled in group B received only a single dose of paroxetine (20 mg) administered`on demand' 3 ± 4 h prior to all intercourses during a period of four weeks.
Men were supplied with an ejaculation diary and were asked to record their frequency of coitus, quality of erection and orgasm, and to measure and record their ejaculatory latency time using a stopwatch. Men were required to attempt coitus on at least two occasions each week.
Statistical analysis
A Student's t-test was used to compare the ELT before and after treatment with paroxetine in Groups A and B
Results
The mean age of the 94 men studied was 39 y (range 18 ± 61 y). The mean pre-treatment ejaculatory latency time was 0.4 min (range 0 ± 1 min). The pretreatment frequency of intercourse was 0.4 timesa week. Fifty-®ve men (59%) had lifelong premature ejaculation, the remaining 39 men (41%) describing acquired premature ejaculation with previous acceptable ejaculatory control. Of the 55 men with lifelong premature ejaculation, 10 men (18%) had severe lifelong premature ejaculation and had never achieved intravaginal ejaculation.
Group A comprised 61 men with a mean age of 40 y (range 22 ± 61), 37 men having lifelong PE and the remaining 24 having acquired PE. Group B comprised 33 men with a mean age of 37 y (range In group A-phase 1,761 intercourses were recorded ( Table 1 ). The mean ELT was 1.1 min after one week of treatment, 1.6 min after two weeks, 3.5 min at three weeks and 4.5 min at four weeks. The ELT was statistically superior to pre-study levels at 2, 3 and 4 weeks (all P`0.001). The mean frequency of intercourse was 2.4 timesaweek. Fiftythree men in this group (87%) regarded their ejaculatory control as signi®cantly better and had an ELT after four weeks of treatment of 5.1 min (range 2 ± 17 min) and a frequency of intercourse of 2.5 timesaweek. The remaining 8 out of 61 men regarded that they had not achieved improved control and had a mean ELT of 0.6 min (range 0 ± 2 min) at four weeks and a frequency of intercourse of 1.7 timesaweek. Lifelong PE was present in 6 men in the cohort of 8 who failed to respond to daily paroxetine. The ELT for the 53 out of 61 men who regarded their ejaculatory control as improved was statistically higher than the remaining 8 out of 61 men who thought that they had not achieved improved control (P`0.001). Of the 53 men in group a who achieved improved ejaculatory control and continued with`on demand' paroxetine (Phase 2), 608 additional intercourses were recorded with a mean ELT of 3.9 min (range 0 ± 10) and a frequency of 2.6 timesaweek (Table 1 ) after a mean follow-up of 4.4 weeks of treatment, one patient was lost to follow up. Thirty-six men (69%) regarded that they had maintained improved ejaculatory control after four weeks of additional treatment with`on-demand' paroxetine, recording 391 intercourses with a mean ELT of 5.5 min (range 2 ± 10) and a frequency of 2.4 intercoursesaweek. The remaining 16 out of 53 men (31%) who regarded that they had failed to maintain improved ejaculatory control recorded 229 intercourses with a mean ELT of 0.6 min (range 0 ± 2 min) at four weeks and a frequency of 2.8 intercoursesaweek. Lifelong PE was present in 11 men in the cohort of 16 who failed to respond to`ondemand' paroxetine. The mean ELT for Group A overall was statistically greater than the pre-study ELT (P`0.001). The mean ELT for men in group Phase 1 and Phase 2 of group a were not statistically different. The ELT for the 36 out of 53 men who regarded that they had maintained improved ejaculatory control was statistically higher than the remaining 16 out of 53 men who felt that they had not maintained improved ejaculatory control (P`0.001).
In Group B, 298 intercourses were recorded with a mean ELT of 1.5 min (range 0 ± 5 min) and a frequency of 2.2 intercoursesaweek after a mean follow-up of 4.1 weeks of treatment (Table 1) . This was statistically greater than the pre-treatment ELT (P`0.05) and statistically less than the mean ELT for Group A-phase 2 (P`0.001). Fourteen out of thirty-three men regarded their ejaculatory control as signi®cantly better and these men had a mean ELT of 2.7 min (range 2 ± 5 min) and a frequency of 2.4 intercoursesaweek. This ELT was statistically superior to the pre-treatment interval (P`0.05). The remaining 19 out of 33 men reported no change in ejaculatory control with a mean ELT of 0.4 min (range 0 ± 2 min) and a frequency of 2.0 intercoursesaweek. Lifelong PE was present in 15 men in the cohort of 19 who failed to respond to`on-demand' paroxetine. This ELT was not statistically superior to the pre-study ELT (P b 0.05).
Intra-vaginal ejaculation was achieved for the ®rst time in 10 out of 10 men with severe lifelong premature ejaculation who had never previously achieved intra-vaginal ejaculation, including four men in Group B.
The drug was, in general well tolerated. Most side effects were minor and only one patient withdrew from the study as a result of anejaculation. Drowsiness and anorexia occurred in 1 out of 61 men, minor gastrointestinal upset in 2 out of 61 men, reduced libido in 3 out of 61, inhibited orgasm despite achieving ejaculation in 3 out of 61 and anejaculation after prolonged intercourse in 5 out of 61 in Group A-Phase 1 (chronic dosing). The mean age of the ®ve men who experienced anejaculation was 26 y (range 19 ± 47) and their mean pre-treatment ELT was 0.9 min. Ejaculation was restored with a lesser dose of paroxetine [(5 mg (n 3), 10 mg (n 1)] in four men with a mean ELT of 18.4 min following dose titration. The remaining man remained unable to ejaculate despite reducing the dose to 5 mg and withdrew from the study. None of the men taking`on demand' paroxetine (Group APhase 2, Group B) reported an adverse effect including anejaculation (Table 2 ). Erectile dysfunction was not reported.
Discussion
Paroxetine has a relatively long half life of 24 h allowing once daily dosing. Peak plasma levels are Treatment of premature ejaculation CG McMahon and K Touma usually achieved within 2 ± 8 h with steady state systemic levels occurring after 7 ± 14 d. 16 It undergoes extensive ®rst pass metabolism principally to conjugates with glucuronic acid and sulphate which have no more than 1a50 the potency of their parent compound at inhibiting serotonin uptake. The only reported contraindication to use of paroxetine, apart from known hypersensitivity, is the concurrent use of monoamine oxidase inhibitors. Paroxetine selectively inhibits serotonin (5-HT) uptake in brain neurons, but unlike sertraline has little af®nity for dopamine receptors and central b-adrenergic receptors. 17 The most common side effects are sexual and gastrointestinal but a very occasional patient will experience the agitation and tremor seen with uoxetine. Drug interactions with warfarin, tryptophan, dilantin have been reported. This study demonstrates that paroxetine prolongs the ejaculatory latency time when it is administered chronically or`on-demand'. Although this study did not employ an inventory of sexual satisfaction for either the men studied or their partners, the observed improved ejaculatory control and increased frequency of intercourse suggest improved sexual response and satisfaction. Delayed ejaculation and as a consequence, improved ejaculatory control, appears to occur within 1 ± 2 weeks of initiating treatment. This acute effect is due to paroxetine's direct blocking effect on central serotonergic re-uptake and cannot be attributed to a decrease in psychopathology since none of the men were clinically depressed. Furthermore, the antidepressant effect of paroxetine has not been reported to occur within 1 ± 2 weeks. It is possible that some of the improved ejaculatory control and any sustained long term improvement after withdrawal of paroxetine could be related to a reduction in performance anxiety due to improved patienta partner perceived sexual success.
Paroxetine administered on a daily basis appears more ef®cacious than`on-demand' paroxetine in the treatment of PE. Only 14 out of 33 men (42%) in group B treated with initial`on-demand' paroxetine (group B) achieved improved ejaculatory control as opposed to 53 out of 61 men (87%) in group A who were treated with daily paroxetine. In addition, the ELT of the latter (5.1 min) is statistically superior to the former (2.7 min) (P`0.05). Clearly, paroxetine administered on a daily basis produces signi®cantly better ejaculatory control in signi®cantly more patients than does`on-demand' paroxetine. However,`on-demand' use of paroxetine appears more ef®cacious after initial chronic dosing. of the 53 men in group A treated with`on-demand' paroxetine after initial daily administration for four weeks, 36 (68%) reported sustained ejaculatory control with an ELT of 5.5 min which was not signi®cantly different from that achieved during the initial daily dosing phase (5.1 min) . Overall, 59% of men in group a (36 out of 61) achieved and maintained improved ejaculatory control with treatment of PE with a combination of initial daily paroxetine followed by`on-demand' paroxetine. A failure to respond to paroxetine treatment in any form is more likely in men with lifelong PE. The observation that initial loading with paroxetine produces`ejaculatory recruitment' may be related to the non-linear pharmacokinetics of paroxetine. As a result of ®rst-pass metabolism which is almost exclusively mediated by the P450 2D6 enzyme, the amount of paroxetine available to the systemic circulation is less than that absorbed from the gastrointestinal tract. 18 ± 20 However, paroxetine is also a potent inhibitor of this enzyme, thereby effectively inhibiting it's own metabolism and demonstrating nonlinear pharmacokinetics. Therefore, as paroxetine concentration increases with multiple dosing, the P450 2D6 activity decreases thus prolonging drug clearance and resulting in a disproportionately greater increase in its concentration with every dose. 21 On the basis of these results, initial treatment with daily paroxetine for four weeks followed by a trial of`on-demand' paroxetine is the preferred approach in that it offers 59% of men improved ejaculatory control with minimal adverse effects. However, treatment`conversion' from daily to`ondemand' paroxetine may be associated with a recurrence of PE. in a signi®cant number of those men who initially responded to daily paroxetine (32% in this study) prompting continuation of daily paroxetine. Patients should be informed of this risk if and when`conversion' to`on-demand' treatment is planned. Initial`on-demand' paroxetine although having no reported adverse effects, is effective in only 42% of men and is most appropriate in those men troubled by the adverse effects of daily paroxetine particularly anejaculation or retarded ejaculation.`On-demand' paroxetine has particular appeal in those men who have less severe PE, have intercourse infrequently andaor prefer to avoid taking daily medication.
Paroxetine appears to be reasonably well tolerated by the men enrolled in this study although treatment with 20 mg paroxetinead was associated Treatment of premature ejaculation CG McMahon and K Touma with anejaculation in 5 out of 61 (8%) men and inhibition of orgasm despite achieving ejaculation in 3 out of 61 (5%) men. One man who experienced anejaculation declined further treatment with paroxetine, the remaining 4 out of 5 men achieving ejaculation with a reduced dose of 5 ± 10 mg. These ®ve men had a mean pre-study ELT of 0.9 min which is higher than that the entire study group (0.4 min) and as such, one would expect a lesser incidence of anejaculation in men with more severe PE especially if lower doses were employed. The occurrence of anejaculation with sertraline, another member of the SSRI class of anti-depressants, has been reported as dose related. McMahon 22 reported that whilst all men in a study group of 46 treated with 25 mg sertralinead managed to ejaculate during intercourse, 4 out of 46 (9%) men treated with 50 mg sertralinead and 10 out of 46 men (22%) treated with 100 mg sertralinead were unable to ejaculate after prolonged intercourse. No correlation has been reported between dose of paroxetine and it's antidepressant effect and the incidence of adverse effects. Crenshaw and Goldberg 23 reported that in their limited clinical experience, the incidence of retarded ejaculation in men treated with paroxetine for depression is dose related, mainly occurring above 20 mg. This parallels the experience of the authors and dose-response studies are currently being conducted. Eight of the 10 men with severe lifelong PE who achieved intravaginal ejaculation for the ®rst time in their sexual life with treatment with paroxetine, had previously undergone and failed to respond to one or more trials of treatment with psychosexual counselling. These men must be considered as suffering from severe and refractory PE, and previous treatment failures. Paroxetine drug treatment salvaged them from life long ejaculatory dysfunction and its relationship sequella.
Conclusions
Paroxetine appears to be a useful and reasonably well tolerated oral treatment for premature ejaculation with improved ejaculatory control usually occurring within 1 ± 2 weeks and subsequent increased frequency of intercourse. On demand administration of paroxetine improves ejaculatory control but appears more ef®cacious after initial chronic dosing.
